Uproleselan

DRUG11 trials

Sponsors

GlycoMimetics Incorporated, National Cancer Institute (NCI), Washington University School of Medicine, Apollomics Inc., M.D. Anderson Cancer Center

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyCOVID-19 PneumoniaHealthy SubjectsMultiple MyelomaMyelodysplastic Syndrome Post Cytotoxic TherapyMyeloid Leukemia Associated With Down SyndromePediatric Cancer

Phase 1

A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)

CompletedNCT03606447

GlycoMimetics IncorporatedHealthy Subjects

Start: 2018-08-14End: 2018-09-13Updated: 2019-05-14

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

CompletedNCT04839341

Apollomics Inc.Relapsed/Refractory AML

Start: 2021-02-24End: 2024-06-28Updated: 2025-06-27

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

CompletedNCT04848974

M.D. Anderson Cancer CenterSecondary Acute Myeloid Leukemia

Start: 2021-06-11End: 2024-10-30Updated: 2026-06-05

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

TerminatedNCT04964505

Brian JonasAcute Myeloid Leukemia

Start: 2021-07-02End: 2025-10-07Updated: 2026-02-23

Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

TerminatedNCT05057221

Lena Napolitano, MDCOVID-19 Pneumonia

Start: 2021-11-12End: 2022-03-09Updated: 2023-07-10

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Active, not recruitingNCT05146739

National Cancer Institute (NCI)Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome +6

Start: 2023-10-10End: 2027-05-09Updated: 2026-06-02

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

TerminatedNCT05569512

Malika KapadiaAcute Myeloid Leukemia, Pediatric Cancer

Start: 2022-10-06End: 2023-12-06Updated: 2024-08-19

Phase 2

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Active, not recruitingNCT03701308

National Cancer Institute (NCI)Acute Myeloid Leukemia

Start: 2019-03-28End: 2026-10-26Updated: 2026-01-21

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

CompletedNCT04682405

Washington University School of MedicineMultiple Myeloma

Start: 2021-05-05End: 2022-11-11Updated: 2023-12-15

Phase 3

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

TerminatedNCT03616470

GlycoMimetics IncorporatedAcute Myeloid Leukemia

Start: 2018-10-15End: 2024-03-31Updated: 2024-07-29

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

TerminatedNCT05054543

Apollomics Inc.Relapsed/Refractory AML

Start: 2021-11-17End: 2024-08-22Updated: 2025-06-27

Related Papers

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood2025-11-03

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Blood2024-11-051 citations

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Blood2024-11-05

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood2024-11-05

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Blood2023-11-022 citations

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Blood2022-11-153 citations

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Blood2022-11-151 citations

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Blood2019-11-133 citations

A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

Journal of Clinical Oncology2019-05-2017 citations